Biblio
Export 2680 results:
[ Author
Filters: First Letter Of Keyword is A [Clear All Filters]
“tRNA-Derived Fragments in Alzheimer's Disease: Implications for New Disease Biomarkers and Neuropathological Mechanisms.”, J Alzheimers Dis, vol. 79, no. 2, pp. 793-806, 2021.
, “tRNA-Derived Fragments in Alzheimer's Disease: Implications for New Disease Biomarkers and Neuropathological Mechanisms.”, J Alzheimers Dis, vol. 79, no. 2, pp. 793-806, 2021.
, “11C-CFT-PET in Presymptomatic FTDP-17: A Potential Biomarker Predicting Onset.”, J Alzheimers Dis, vol. 61, no. 2, pp. 613-618, 2018.
, “Circulating microRNAs as Biomarkers of Alzheimer's Disease: A Systematic Review.”, J Alzheimers Dis, vol. 49, no. 3, pp. 755-66, 2016.
, “Microglia-Astrocyte Communication in Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 3, pp. 785-803, 2023.
, “Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 92, no. 1, pp. 311-322, 2023.
, “Meta-Analysis of Transcriptome Data Related to Hippocampus Biopsies and iPSC-Derived Neuronal Cells from Alzheimer's Disease Patients Reveals an Association with FOXA1 and FOXA2 Gene Regulatory Networks.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1065-82, 2016.
, “Race/Ethnic Disparities in Mild Cognitive Impairment and Dementia: The Northern Manhattan Study.”, J Alzheimers Dis, vol. 80, no. 3, pp. 1129-1138, 2021.
, “Race/Ethnic Disparities in Mild Cognitive Impairment and Dementia: The Northern Manhattan Study.”, J Alzheimers Dis, vol. 80, no. 3, pp. 1129-1138, 2021.
, “Comparison of Prefrontal Atrophy and Episodic Memory Performance in Dysexecutive Alzheimer's Disease and Behavioral-Variant Frontotemporal Dementia.”, J Alzheimers Dis, vol. 51, no. 3, pp. 889-903, 2016.
, “Comparison of Prefrontal Atrophy and Episodic Memory Performance in Dysexecutive Alzheimer's Disease and Behavioral-Variant Frontotemporal Dementia.”, J Alzheimers Dis, vol. 51, no. 3, pp. 889-903, 2016.
, “Comparison of Prefrontal Atrophy and Episodic Memory Performance in Dysexecutive Alzheimer's Disease and Behavioral-Variant Frontotemporal Dementia.”, J Alzheimers Dis, vol. 51, no. 3, pp. 889-903, 2016.
, “Lithium Provides Broad Therapeutic Benefits in an Alzheimer's Disease Mouse Model.”, J Alzheimers Dis, vol. 91, no. 1, pp. 273-290, 2023.
, “Lithium Provides Broad Therapeutic Benefits in an Alzheimer's Disease Mouse Model.”, J Alzheimers Dis, vol. 91, no. 1, pp. 273-290, 2023.
, “Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 1, pp. 95-107, 2023.
, “Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 1, pp. 95-107, 2023.
, “Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 1, pp. 95-107, 2023.
, “Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 1, pp. 95-107, 2023.
, “Thyroid-Stimulating Hormone and Mild Cognitive Impairment: Results of the Heinz Nixdorf Recall Study.”, J Alzheimers Dis, vol. 49, no. 3, pp. 797-807, 2016.
, “Thyroid-Stimulating Hormone and Mild Cognitive Impairment: Results of the Heinz Nixdorf Recall Study.”, J Alzheimers Dis, vol. 49, no. 3, pp. 797-807, 2016.
, “Cohort Effects in the Prevalence and Survival of People with Dementia in a Rural Area in Northern Sweden.”, J Alzheimers Dis, vol. 50, no. 2, pp. 387-96, 2016.
, “Cohort Effects in the Prevalence and Survival of People with Dementia in a Rural Area in Northern Sweden.”, J Alzheimers Dis, vol. 50, no. 2, pp. 387-96, 2016.
, “Cohort Effects in the Prevalence and Survival of People with Dementia in a Rural Area in Northern Sweden.”, J Alzheimers Dis, vol. 50, no. 2, pp. 387-96, 2016.
, “Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.”, J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.
, “Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.”, J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.
,